Global Antibody-oligonucleotide Conjugates (AOCs) Market 2025 by Company, Regions, Type and Application, Forecast to 2031

May 2025 | 95 pages | ID: G4D8D7533C26EN
GlobalInfoResearch

Abstracts

According to our latest research, the global Antibody-oligonucleotide Conjugates (AOCs) market size will reach USD 1438 million in 2031, growing at a CAGR of 17.8% over the analysis period.

AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.

The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.

The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.

The Antibody-oligonucleotide Conjugates (AOCs) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation

Antibody-oligonucleotide Conjugates (AOCs) market is split by Type and by Application. For the period 2025-2031, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

• Chemical Coupling
• Enzymatic Coupling

Market segment by Application, can be divided into

• Pharmaceuticals
• Scientific Research

Market segment by players, this report covers

• Avidity Biosciences
• Dyne Therapeutics
• Tallac Therapeutics
• Creative Biolabs
• Abzena
• BOCSCI Inc.
• Wuxi AppTec
• Lonza
• Leinco

Market segment by regions, regional analysis covers

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Antibody-oligonucleotide Conjugates (AOCs)
1.2 Classification of Antibody-oligonucleotide Conjugates (AOCs) by Type
  1.2.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type: 2025 Versus 2031
  1.2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type in 2031
  1.2.3 Chemical Coupling
  1.2.4 Enzymatic Coupling
1.3 Global Antibody-oligonucleotide Conjugates (AOCs) Market by Application
  1.3.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application: 2025 Versus 2031
  1.3.2 Pharmaceuticals
  1.3.3 Scientific Research
1.4 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size & Forecast
1.5 Market Drivers, Restraints and Trends
  1.5.1 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
  1.5.2 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
  1.5.3 Antibody-oligonucleotide Conjugates (AOCs) Trends Analysis

2 COMPANY PROFILES

2.1 Avidity Biosciences
  2.1.1 Avidity Biosciences Details
  2.1.2 Avidity Biosciences Major Business
  2.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.1.4 Avidity Biosciences Recent Developments and Future Plans
2.2 Dyne Therapeutics
  2.2.1 Dyne Therapeutics Details
  2.2.2 Dyne Therapeutics Major Business
  2.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.2.4 Dyne Therapeutics Recent Developments and Future Plans
2.3 Tallac Therapeutics
  2.3.1 Tallac Therapeutics Details
  2.3.2 Tallac Therapeutics Major Business
  2.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.3.4 Tallac Therapeutics Recent Developments and Future Plans
2.4 Creative Biolabs
  2.4.1 Creative Biolabs Details
  2.4.2 Creative Biolabs Major Business
  2.4.3 Creative Biolabs Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.4.4 Creative Biolabs Recent Developments and Future Plans
2.5 Abzena
  2.5.1 Abzena Details
  2.5.2 Abzena Major Business
  2.5.3 Abzena Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.5.4 Abzena Recent Developments and Future Plans
2.6 BOCSCI Inc.
  2.6.1 BOCSCI Inc. Details
  2.6.2 BOCSCI Inc. Major Business
  2.6.3 BOCSCI Inc. Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.6.4 BOCSCI Inc. Recent Developments and Future Plans
2.7 Wuxi AppTec
  2.7.1 Wuxi AppTec Details
  2.7.2 Wuxi AppTec Major Business
  2.7.3 Wuxi AppTec Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.7.4 Wuxi AppTec Recent Developments and Future Plans
2.8 Lonza
  2.8.1 Lonza Details
  2.8.2 Lonza Major Business
  2.8.3 Lonza Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.8.4 Lonza Recent Developments and Future Plans
2.9 Leinco
  2.9.1 Leinco Details
  2.9.2 Leinco Major Business
  2.9.3 Leinco Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
  2.9.4 Leinco Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue and Share by Players (2025 & 2031)
3.2 Antibody-oligonucleotide Conjugates (AOCs) Players Head Office, Products and Services Provided
3.3 Antibody-oligonucleotide Conjugates (AOCs) Mergers & Acquisitions
3.4 Antibody-oligonucleotide Conjugates (AOCs) New Entrants and Expansion Plans

4 GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (AOCS) FORECAST BY REGION

4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2025 VS 2031
4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region, (2025-2031)
4.3 North America
  4.3.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in North America
  4.3.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in North America
  4.3.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2025-2031)
4.4 Europe
  4.4.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Europe
  4.4.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Europe
  4.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2025-2031)
4.5 Asia-Pacific
  4.5.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
  4.5.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
  4.5.3 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2025-2031)
  4.5.4 China
  4.5.5 Japan
  4.5.6 South Korea
4.6 South America
  4.6.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South America
  4.6.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in South America
  4.6.3 South America Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2025-2031)
4.7 Middle East & Africa
  4.7.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
  4.7.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
  4.7.3 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2025-2031)

5 MARKET SIZE SEGMENT BY TYPE

5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Forecast by Type (2025-2031)
5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Type (2025-2031)

6 MARKET SIZE SEGMENT BY APPLICATION

6.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Forecast by Application (2025-2031)
6.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Application (2025-2031)

7 RESEARCH FINDINGS AND CONCLUSION

8 APPENDIX

8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Type, (USD Million) 2025 VS 2031
Table 2. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Application, (USD Million), 2025 VS 2031
Table 3. Avidity Biosciences Corporate Information, Head Office, and Major Competitors
Table 4. Avidity Biosciences Major Business
Table 5. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 6. Dyne Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Dyne Therapeutics Major Business
Table 8. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 9.Tallac Therapeutics Corporate Information, Head Office, and Major Competitors
Table 10.Tallac Therapeutics Major Business
Table 11.Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 12. Creative Biolabs Corporate Information, Head Office, and Major Competitors
Table 13. Creative Biolabs Major Business
Table 14. Creative Biolabs Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 15. Abzena Corporate Information, Head Office, and Major Competitors
Table 16. Abzena Major Business
Table 17. Abzena Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 18. BOCSCI Inc. Corporate Information, Head Office, and Major Competitors
Table 19. BOCSCI Inc. Major Business
Table 20. BOCSCI Inc. Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 21. Wuxi AppTec Corporate Information, Head Office, and Major Competitors
Table 22. Wuxi AppTec Major Business
Table 23. Wuxi AppTec Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 24. Lonza Corporate Information, Head Office, and Major Competitors
Table 25. Lonza Major Business
Table 26. Lonza Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 27. Leinco Corporate Information, Head Office, and Major Competitors
Table 28. Leinco Major Business
Table 29. Leinco Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 30. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) by Players (2025 & 2031)
Table 31. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Share by Players (2025 & 2031)
Table 32. Antibody-oligonucleotide Conjugates (AOCs) Players Head Office, Products and Services Provided
Table 33. Antibody-oligonucleotide Conjugates (AOCs) Mergers & Acquisitions in the PastFive Years
Table 34. Antibody-oligonucleotide Conjugates (AOCs) New Entrants and Expansion Plans
Table 35. Global Market Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) Comparison by Region (2025 VS 2031)
Table 36. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region (2025-2031)
Table 37. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in North America
Table 38. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in North America
Table 39. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Europe
Table 40. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Europe
Table 41. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
Table 42. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
Table 43. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in China
Table 44. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Japan
Table 45. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South Korea
Table 46. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South America
Table 47. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in South America
Table 48. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
Table 49. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
Table 50. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Forecast by Type (2025-2031)
Table 51. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Forecast by Application (2025-2031)

List Of Figures

LIST OF FIGURES

Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture
Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type in 2031
Figure 3. Chemical Coupling
Figure 4. Enzymatic Coupling
Figure 5. Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application in 2031
Figure 6. Pharmaceuticals Picture
Figure 7. Scientific Research Picture
Figure 8. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (USD Million): 2025 VS 2031
Figure 9. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue and Forecast (2025-2031) & (USD Million)
Figure 10. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
Figure 11. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
Figure 12. Antibody-oligonucleotide Conjugates (AOCs) Market Trends
Figure 13. Avidity Biosciences Recent Developments and Future Plans
Figure 14. Dyne Therapeutics Recent Developments and Future Plans
Figure 15.Tallac Therapeutics Recent Developments and Future Plans
Figure 16. Creative Biolabs Recent Developments and Future Plans
Figure 17. Abzena Recent Developments and Future Plans
Figure 18. BOCSCI Inc. Recent Developments and Future Plans
Figure 19. Wuxi AppTec Recent Developments and Future Plans
Figure 20. Lonza Recent Developments and Future Plans
Figure 21. Leinco Recent Developments and Future Plans
Figure 22. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region (2025-2031)
Figure 23. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region in 2031
Figure 24. North America Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2025-2031)
Figure 25. Europe Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2025-2031)
Figure 26. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2025-2031)
Figure 27. South America Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2025-2031)
Figure 28. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2025-2031)
Figure 29. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Type (2025-2031)
Figure 30. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Application (2025-2031)
Figure 31. Methodology
Figure 32. Research Process and Data Source